First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: ...
Dr. Christopher Seet, an assistant professor of hematology-oncology at the David Geffen School of Medicine at UCLA, has received a $2.9 million R37 MERIT Award from the National Cancer Institute to ...